|
ONDCP Cascade of Care for Substance Use Disorders Interagency Workgroup Subcommittee Metrics
|
Committee, Work group, Advisory group, or Task Force
|
Not Reported
|
NIDA
|
ONDCP
|
|
ONDCP Cascade of Care for Substance Use Disorders Interagency Workgroup Subcommittee Training
|
Committee, Work group, Advisory group, or Task Force
|
Not Reported
|
NIDA
|
ONDCP
|
|
ONDCP Drug Data Equity Subcommittee
|
Committee, Work group, Advisory group, or Task Force
|
Not Reported
|
NIDA
|
The ONDCP Data Interagency Working Group (IWG) is led by ONDCP to review and recommend drug data and research to address the policy priorities articulated by the current Administration. Agency contributions will help inform and be incorporated into the 2022 National Drug Control Strategy. This subcommittee is focused on information sharing on other federally funded research and initiatives focused on data equity.
|
|
ONDCP Drug Data IWG
|
Committee, Work group, Advisory group, or Task Force
|
Not Reported
|
NIDA
|
The ONDCP Data Interagency Working Group (IWG) is led by ONDCP to review and recommend drug data and research to address the policy priorities articulated by the current Administration. Agency contributions will help inform and be incorporated into the 2022 National Drug Control Strategy.
|
|
ONDCP Drug Data Nonfatal Overdose Subcommittee
|
Committee, Work group, Advisory group, or Task Force
|
Not Reported
|
NIDA
|
The ONDCP Data Interagency Working Group (IWG) is led by ONDCP to review and recommend drug data and research to address the policy priorities articulated by the current Administration. Agency contributions will help inform and be incorporated into the 2022 National Drug Control Strategy.
|
|
ONDCP Drug Data Wastewater subcommittee
|
Committee, Work group, Advisory group, or Task Force
|
Not Reported
|
NIDA
|
The ONDCP Data Interagency Working Group (IWG) is led by ONDCP to review and recommend drug data and research to address the policy priorities articulated by the current Administration. Agency contributions will help inform and be incorporated into the 2022 National Drug Control Strategy. This subcommittee is focused on information sharing on research and initiatives around wastewater both in the U.S. and in other countries.
|
|
ONDCP Evolving and Emerging Threats Committee
|
Committee, Work group, Advisory group, or Task Force
|
Not Reported
|
NIDA
|
The Committee is responsible for supporting ONDCP’s efforts to designate and terminate the designation of evolving and emerging drug threats.
|
|
ONDCP Harm Reduction Interagency Working Group - Reimbursement Subgroup
|
Committee, Work group, Advisory group, or Task Force
|
ASPE, CDC, CMS, HRSA
|
NIDA
|
This interagency working group (IWG) will help drive action in support of the Biden-Harris Administration goal of increasing access to evidence-based harm reduction services through expanded Medicaid reimbursement, comprehensive federal grant funding, research, and workforce training. Specifically, the IWG will focus on integrating harm reduction services with traditional health care infrastructure by developing sustainable funding streams needed to expand the availability of syringe services programs, naloxone, fentanyl test strips, and low-threshold medication treatment for opioid use disorder at harm reduction programs, as outlined in the 2022 National Drug Control Strategy.
|
|
ONDCP Harm Reduction Interagency Working Group - Research Subgroup
|
Committee, Work group, Advisory group, or Task Force
|
ASPE, CDC, CMS, HRSA, SAMHSA
|
NIDA
|
This interagency working group (IWG) will help drive action in support of the Biden-Harris Administration goal of increasing access to evidence-based harm reduction services through expanded Medicaid reimbursement, comprehensive federal grant funding, research, and workforce training. Specifically, the IWG will focus on integrating harm reduction services with traditional health care infrastructure by developing sustainable funding streams needed to expand the availability of syringe services programs, naloxone, fentanyl test strips, and low-threshold medication treatment for opioid use disorder at harm reduction programs, as outlined in the 2022 National Drug Control Strategy.
|
|
ONDCP Recovery Research Interagency Working Group
|
Committee, Work group, Advisory group, or Task Force
|
AHRQ, ASPE, CDC, CMS, IHS, IOS, SAMHSA
|
NIAAA, NIDA
|
To develop, prioritize, and coordinate the implementation of a federal recovery research agenda across agencies. Through this IWG, which is called for in the President’s National Drug Control Strategy (NDCS), we will assess the current scientific knowledge of recovery from SUD, review federally funded research, evaluation, and data collection portfolios/strategies, and identify areas where additional research and evaluation efforts should be prioritized to support science-based policy.
|